Vijay K Iyengar has sold INCY and made no open-market buys since Jan 2018

Vijay K. Iyengar, MD, is the Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAPPS) at Incyte Corporation, a Delaware‑incorporated biopharmaceutical company, where he serves as a senior corporate officer and reporting insider under the title EVP, GMAPPS.( As an Incyte insider, he has executed multiple Form 4‑reported transactions in the company’s common stock, including disposals of shares in 2024 and 2025, reflecting his ongoing equity participation in the business.( These SEC filings confirm that Iyengar reports as one reporting person, underscoring that he is an individual corporate executive rather than a separate corporate entity.(

Dr. Iyengar joined Incyte in 2016 as Executive Vice President, Global Strategy and Corporate Development, and in 2022 his responsibilities were expanded to encompass leadership of Global Product Strategy, Value, Access and Pricing, Business Development, Alliance Management, Rest‑of‑World partnerships, and Global Medical Affairs.( He brings more than 20 years of pharmaceutical industry experience, including serving as President of Genoptix Corporation, a Novartis company providing oncology diagnostic testing and clinical trial assay services, and holding senior leadership roles at Novartis such as Vice President and Rare Diseases Franchise Head at Novartis Oncology and Oncology General Manager of Novartis Greece.( Earlier in his career, he was an Engagement Manager at McKinsey & Company in its healthcare practice.( Dr. Iyengar holds a Bachelor of Science in Biology from Stanford University and an M.D. from Harvard Medical School, credentials that underpin his combined medical, scientific, and strategic expertise in the biopharmaceutical sector.(

Written by Perplexity from public sources.